Berenberg Bank reaffirmed their buy rating on shares of Smith & Nephew (LON:SN – Free Report) in a research note released on Thursday morning, MarketBeat reports. They currently have a GBX 1,450 ($18.21) price objective on the stock.
A number of other research firms also recently commented on SN. Royal Bank of Canada reaffirmed an outperform rating and issued a GBX 1,500 ($18.84) price objective on shares of Smith & Nephew in a report on Friday, April 5th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 1,300 ($16.33) price target on shares of Smith & Nephew in a report on Thursday, April 18th. Finally, Barclays reissued an equal weight rating and set a GBX 1,150 ($14.45) price target on shares of Smith & Nephew in a report on Friday, February 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Smith & Nephew has a consensus rating of Moderate Buy and an average price target of GBX 1,346.20 ($16.91).
View Our Latest Analysis on Smith & Nephew
Smith & Nephew Stock Up 1.1 %
Smith & Nephew Increases Dividend
The firm also recently disclosed a dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Thursday, March 28th will be given a $0.23 dividend. This represents a dividend yield of 1.62%. This is a boost from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date is Thursday, March 28th. Smith & Nephew’s dividend payout ratio is currently 12,500.00%.
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Further Reading
- Five stocks we like better than Smith & Nephew
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 4/29 – 5/3
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- P/E Ratio Calculation: How to Assess Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.